ESG vs Gastric Sleeve: Incisionless Stitching vs Surgical Sleeve Gastrectomy

They share a name and a shape — both turn the stomach into a narrow tube — but endoscopic sleeve gastroplasty (ESG) and surgical sleeve gastrectomy are very different procedures with very different trade-offs. ESG is incisionless: a gastroenterologist stitches the stomach smaller from the inside, through the mouth, removing nothing. The surgical sleeve is an operation: a bariatric surgeon staples off and permanently cuts away roughly 70–80% of the stomach. The weight-loss gap is real and runs one way — ESG produced about 13.6% total body weight loss (TBWL) at one year in the pivotal MERIT randomized trial^[1], while surgical sleeve gastrectomy delivers roughly 25–30% TBWL and holds it for a decade^[4][5]. But the risk, reversibility, and recovery gaps run the other way. This article lays out the honest comparison — efficacy, durability, safety, reversibility, cost, and how both stack up against a GLP-1 like semaglutide (~14.9% TBWL^[7]) — so you can decide between the incisionless procedure, the operation, and the injection.

The honest summary

• The surgical sleeve wins on weight loss; ESG wins on everything else about risk and reversibility. Surgical sleeve gastrectomy takes off roughly 25–30% of total body weight and keeps most of it off for 10 years^[4][5]. ESG takes off about 13.6% at one year^[1] and near 16% at five years^[3] — roughly half the surgical figure, but through an incisionless, lower-risk, potentially reversible route.
• ESG is incisionless and outpatient; the surgical sleeve is real abdominal surgery. ESG is done through the mouth under sedation in about 60–90 minutes with no external scar and same-day discharge. The surgical sleeve is a laparoscopic operation under general anesthesia, with a hospital stay and a multi-week recovery.
• ESG removes nothing and keeps the door open; the surgical sleeve is permanent. ESG places sutures that can loosen, be removed, or be revised — and it does not burn the bridge to a future surgical sleeve or bypass. Surgical sleeve gastrectomy permanently excises most of the stomach and cannot be undone.
• Both are far safer than obesity's historical surgery reputation, but the surgical sleeve carries more procedural risk. ESG's pooled serious adverse-event rate is about 2% with no deaths in the major series^[2]. Surgical sleeve gastrectomy is also low-risk in modern practice but involves staple lines, leaks, and the fixed risks of general surgery.
• There is no head-to-head ESG-vs-surgical-sleeve randomized trial. Every efficacy comparison here is cross-trial and directional. What we do have is a strong ESG RCT (MERIT^[1]) and strong surgical-sleeve RCTs (SLEEVEPASS^[4], SM-BOSS^[5]), plus the STAMPEDE surgery-vs-medical-therapy trial^[6].
• BMI matters for who each one is aimed at. ESG's evidence base is class 1–2 obesity (BMI ~30–40)^[1] — often people who don't qualify for or don't want surgery. Surgical sleeve gastrectomy is the workhorse for higher-BMI patients and those needing the largest, most durable loss.
• A GLP-1 sits between them on weight loss and outside them on route. Semaglutide (~14.9% TBWL^[7]) lands close to ESG and below the surgical sleeve, but it is a non-invasive weekly injection whose effect tends to fade if you stop — a different structural bet than either procedure.

Same shape, different procedure: what actually happens

Both procedures shrink the stomach into a tube so it fills faster and empties more slowly — that shared mechanism is why they share a name. The difference is how the tube is made, and it drives everything else.

Endoscopic sleeve gastroplasty (ESG) is a form of bariatric endoscopy. The gastroenterologist passes a flexible endoscope fitted with a suturing device down through the mouth and places a running line of full-thickness stitches along the greater curvature, cinching the stomach into a narrow sleeve from the inside. Nothing is cut, stapled shut, or removed. There is no external incision, it is typically an outpatient procedure under general anesthesia or deep sedation, and most people go home the same day and back to work within roughly a week.

Surgical sleeve gastrectomy is a laparoscopic operation. Through several small abdominal incisions, the surgeon staples along the stomach and permanently removes about 70–80% of it, leaving a banana-shaped tube. Because tissue is excised, the change is anatomical and irreversible, and part of the effect is hormonal (removing the fundus lowers the hunger hormone ghrelin), not just restrictive. It requires general anesthesia, usually an overnight or short hospital stay, and a staged return to normal eating and activity over several weeks.

How much weight? The randomized and long-term evidence

For ESG, the anchor is the MERIT randomized controlled trial (Abu Dayyeh 2022, Lancet^[1]), which randomized 209 adults with a BMI of 30–40 to ESG plus lifestyle or lifestyle alone. ESG produced 13.6% total body weight loss at 52 weeks versus 0.8% for lifestyle counseling, with 77% of ESG patients reaching at least 25% excess weight loss versus 12% of controls, and 68% still holding that responder threshold at 104 weeks. Pooled meta-analysis (Hedjoudje 2020^[2]) puts ESG at 15–17% TBWL across the first two years, and a five-year cohort (Sharaiha 2021^[3]) reported 15.9% TBWL maintained at five years — durable, and far beyond a gastric balloon's six-month window.

For the surgical sleeve, the anchors are the head-to-head sleeve-vs-bypass randomized trials. SLEEVEPASS (Salminen 2022, JAMA Surg^[4]) followed patients for 10 years and found sleeve gastrectomy produced roughly 25% total weight loss, with gastric bypass modestly higher — durable at a decade. SM-BOSS (Peterli 2018, JAMA^[5]) showed sleeve gastrectomy delivering large, sustained loss comparable to bypass at five years. And STAMPEDE (Schauer 2017, NEJM^[6]) established that bariatric surgery beats intensive medical therapy for type 2 diabetes at five years — the strongest metabolic-outcome evidence, which ESG's shorter record cannot yet match. The plain reading: the surgical sleeve loses roughly double what ESG does, and has the longer, harder-outcome track record.

ESG vs surgical sleeve vs bypass vs GLP-1: the cross-comparison

Most people deciding between the incisionless procedure and the operation also have a GLP-1 on the table. Here is the honest cross-comparison — with the essential caveat that no head-to-head trial compares ESG against the surgical sleeve, so these are cross-trial numbers, not a direct contest.

The takeaways from that table:

• The surgical sleeve is the weight-loss winner by a wide margin — roughly 25–30% TBWL^[4][5] versus ESG's ~14–16%^[1][3]. If maximum, most durable weight loss is the goal, surgery is the more powerful tool, full stop.
• ESG buys back risk, recovery, and reversibility for that lost magnitude. Incisionless, ~2% serious complications^[2], same-day discharge, nothing removed, and a preserved option to have surgery later. For many people that trade is worth giving up some pounds.
• A GLP-1 lands almost exactly where ESG does on weight loss^[1][7] but by a completely different route — a non-invasive weekly injection with proven cardiometabolic benefits, whose effect reverses if you stop. Neither the surgical sleeve nor ESG requires a lifelong prescription.
• The three are not mutually exclusive over time. A common real-world path is a GLP-1 first, ESG as a durable step up without surgery, and the surgical sleeve reserved for those who need the largest loss — and because ESG removes no tissue, that surgical door stays open.

For the full drug-versus-procedure and surgery economics, see our bariatric surgery vs GLP-1s review, the dedicated ESG vs GLP-1 comparison, and the deeper ESG evidence review.

Considering a GLP-1 instead of either procedure? Top vetted providers

Safety and recovery: where the procedures really diverge

This is where ESG earns its place. Both procedures are safe by the standards of obesity treatment, but the risk and recovery profiles are not the same.

• ESG serious complications run about 2%. Pooled severe adverse events were 2.2% (Hedjoudje 2020^[2]) — mainly gastrointestinal bleeding and peri-gastric fluid collections — with no procedure-related deaths in the major series^[1][3] and 1.3% moderate events at five years^[3]. Expected temporary effects are a few days of abdominal pain and nausea.
• Surgical sleeve gastrectomy adds the risks of an operation. It involves a staple line (with a small leak risk), general anesthesia, and the fixed hazards of abdominal surgery, plus a recognized long-term risk of new or worsened acid reflux — a signal seen across the sleeve-vs-bypass randomized trials^[4][5]. Modern laparoscopic sleeve surgery is still low-risk, but the floor is higher than an incisionless suturing procedure.
• Recovery timelines differ by design. ESG is outpatient with a roughly one-week return to normal activity. The surgical sleeve typically means a short hospital stay and a staged, multi-week recovery with a structured post-op diet.
• Reversibility is the sharpest divide. ESG places sutures — they can loosen, be removed, or be revised, and the procedure can be redone or converted to surgery. Surgical sleeve gastrectomy permanently removes most of the stomach and cannot be reversed.

For a fuller comparison of surgical risk across sleeve, bypass, and band, see what is the safest form of weight-loss surgery.

Cost and insurance: the trade-off flips

The money math runs opposite to the medical math. Surgical sleeve gastrectomy is frequently covered by insurance when standard medical criteria (BMI thresholds, comorbidities, documented attempts) are met — it is an established, guideline-endorsed operation. ESG is usually paid out of pocket, typically quoted at roughly $8,000–$20,000 in the US, because most insurers still classify it as investigational. So the lower-risk, less-invasive option is often the more expensive one for the patient, while the bigger operation may cost less after coverage. Run your own numbers over a realistic horizon — see how much weight-loss surgery costs and what insurance covers. (Cost figures here are current US market ranges, not a trial-derived number.)

Which one is actually for you?

A reasonable way to sort the decision:

• Lean toward the surgical sleeve if you need the largest, most durable weight loss, have higher-BMI obesity or significant metabolic disease (where surgery's diabetes-outcome evidence is strongest^[6]), qualify for insurance coverage, and are comfortable with permanent anatomy change and an operation.
• Lean toward ESG if you have class 1–2 obesity (BMI ~30–40, the MERIT population^[1]), want a durable, one-time result without an operation, prioritize low procedural risk and fast recovery, want to avoid removing stomach tissue, and can pay out of pocket — while keeping surgery available as a future step.
• Lean toward a GLP-1 first if you want a non-invasive start, value at least partial insurance coverage and proven cardiometabolic benefits, and are willing to stay on treatment — it lands near ESG on weight loss^[7] with no procedure at all, and can precede either procedure.
• Consider sequencing. Because ESG and GLP-1s preserve the surgical option, many people move up the ladder over time rather than choosing once. See our GLP-1 as a bridge to surgery decision guide and the broader endoscopic weight-loss options and gastric balloon reviews.

What we still don't know

• No head-to-head ESG-vs-surgical-sleeve randomized trial exists. Every efficacy and safety comparison here is cross-trial and should be read as directional, not definitive.
• ESG's long-term hard-outcome data are thinner than surgery's. ESG has strong 1-to-5-year weight and metabolic data^[1][3], but nothing like the decade-plus mortality and diabetes-remission outcomes behind sleeve gastrectomy and bypass^[4][6].
• Real-world regain rates outside expert centers, and durability beyond five years for ESG, are still being characterized. Both procedures restrict the stomach; neither removes the need for sustained behavior change.
• How ESG and the surgical sleeve each combine with the newer, more potent GLP-1/GIP drugs has not been settled in large trials.

Bottom line

• Surgical sleeve gastrectomy produces roughly double the weight loss of ESG (~25–30% vs ~13.6–16% TBWL^[1][3][4]) and has the longer, stronger outcome record^[5][6] — but it is permanent surgery that removes most of the stomach.
• ESG gives up that magnitude in exchange for being incisionless, outpatient, lower-risk (~2% serious complications^[2]), and potentially reversible, while preserving the option to have surgery later.
• A GLP-1 lands near ESG on weight loss^[7] by a non-invasive route, and neither procedure is a lifelong prescription — the three can be sequenced rather than chosen once.
• There is no head-to-head ESG-vs-surgical-sleeve trial, so treat the numbers as directional; the choice hinges on how much weight loss you need against how much risk, permanence, and cost you'll accept.
• Both restrict the stomach but neither does the eating for you — sustained behavior change protects either result.

Related research

• Endoscopic sleeve gastroplasty (ESG): the full evidence review — efficacy, safety, cost, and reversibility in depth
• ESG vs GLP-1 (semaglutide and tirzepatide) — the incisionless procedure against the injections
• Endoscopic weight-loss options — ESG, balloons, and the wider non-surgical procedure landscape
• Gastric balloon weight loss — the lighter, temporary endoscopic option
• What is the safest form of weight-loss surgery? — sleeve, bypass, and band risk compared
• How much is weight-loss surgery? — the cost breakdown ESG competes against
• Does insurance cover weight-loss surgery? — why the surgical sleeve is often covered while ESG usually isn't
• Bariatric surgery vs GLP-1s — the full drugs-vs-surgery comparison
• GLP-1 as a bridge to bariatric surgery — sequencing drugs and procedures

Important disclaimer. This article is educational and does not constitute medical advice. Endoscopic sleeve gastroplasty and sleeve gastrectomy are invasive procedures with real risks; suitability depends on your BMI, health, and goals, and must be assessed by a qualified bariatric endoscopist, bariatric surgeon, or obesity-medicine physician. There is no head-to-head trial comparing ESG with surgical sleeve gastrectomy, and cross-trial comparisons with each other and with GLP-1 drugs are not head-to-head and should be interpreted with care. Cost figures are current US market ranges, not trial-derived. Do not start, stop, or change any treatment based on this article. PMIDs were independently verified against the PubMed E-utilities API on 2026-07-01.

Last verified: 2026-07-01. Next review: every 12 months, or sooner if a head-to-head ESG-vs-surgical-sleeve trial or a major long-term ESG outcome study is published.